<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755517</url>
  </required_header>
  <id_info>
    <org_study_id>HPV400</org_study_id>
    <nct_id>NCT04755517</nct_id>
  </id_info>
  <brief_title>Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)</brief_title>
  <acronym>HPV400</acronym>
  <official_title>Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women - A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tampere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify: 1) Whether being informed infrequently results about screening is at least as a)&#xD;
      safe and b) accurate as frequently obtaining all information from (the present combination of&#xD;
      opportunistic/organized) cervical screening by comparing regimen results of two screening&#xD;
      visits at the ages of 25 and 28 years (Arm A1) vs. results of one screening visit at the age&#xD;
      of 28 years (Arm A2) in unvaccinated herd effect protected women. Unvaccinated, frequently&#xD;
      screened women, who are not under herd effect protection will be controls (C).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Altogether 14.000 1995-1997 born women resident in communities where herd effect against&#xD;
      high-risk HPV infections was created with gender-neutral vaccination of birth cohorts&#xD;
      1992-1995 (A-communities) or not (control C-communities) in 2007-2010 with the bi-valent&#xD;
      HPV16/18 vaccine will be invited to participate a randomized screening trial at the ages of&#xD;
      25 and 28 years.&#xD;
&#xD;
      Cervical samples will be analysed for HPV DNA with MGP (Modified General Primer) primer&#xD;
      system followed by MALDITOF(matrix assisted laser desorption ionization-time of flight mass&#xD;
      spectrometry) mass spectrometry on the SEQUENOM (translation of genomic science into&#xD;
      solutions for molecular medicine and biomedical research) platform (HPV).&#xD;
&#xD;
      With assumed 65% and 90% participation and retain rates the trial has 80% power to show&#xD;
      non-inferiority of the infrequent vs. the frequent screening information.&#xD;
&#xD;
      At the study-end testing the null hypotheses of no difference in the incidence of the CIN2/3&#xD;
      (cervical squamous intraepithelial neoplasia 2/3) end-points comparing the A1 vs. C and A2&#xD;
      vs. C intervention arms will be done using the Mantel-Haenszel one degree of freedom&#xD;
      chi-square statistics.&#xD;
&#xD;
      Work Content Letters of invitation to visit cervical screening at the nearest FICAN&#xD;
      (Comprehensive Cancer Center Finland)-Mid study site will be send to the approximately 14.000&#xD;
      unvaccinated women at the ages of 25 and 28 years Following informed consent cervical&#xD;
      liquid-based cytology samples will be taken for HPV DNA and/or cytology screening at study&#xD;
      visits.&#xD;
&#xD;
      All cytological screening results will be communicated to Arm A1 and Arm C study&#xD;
      participants. Arm A2 participants will get the test results at the age of 28. However,&#xD;
      results of the cytology testing indicative of colposcopy according to local standard of care&#xD;
      and currently accepted EU (the European Union) -guidelines (Käypä Hoito 2010, Franceschi et&#xD;
      al. 2011) will be immediately communicated to all study participants. HPV DNA results will be&#xD;
      communicated to all study participants at the study end. Pertinent colposcopy referrals to&#xD;
      organized health care will be made.&#xD;
&#xD;
      All study participants will be offered a possibility to give an oropharyngeal sputum sample&#xD;
      after 30 seconds gargling of sterile physiological saline (5 ml) for HPV PCR (polymerase&#xD;
      chain reaction) analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Frequent / Infrequent information of cytological screening results</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between arm A1 vs. arm C</measure>
    <time_frame>Three years of follow up within 2020 - 2025</time_frame>
    <description>No significant difference in the incidence ratios of CIN2/3 between arms A1 (participants under herd protection and frequently informed of the cytological results) vs. C (participants not under herd protection and frequently informed of the cytological findings) at the age of 28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The difference between arm A2 vs. arm C</measure>
    <time_frame>Three years of follow up within 2020 - 2025</time_frame>
    <description>No significant difference in the incidence ratios of CIN2/3 between arms A2 (participants under herd protection and frequently informed of the cytological results) vs. C (participants not under herd protection and frequently informed of the cytological findings) at the age of 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life in infrequently vs. frequently screened unvaccinated women (RAND 36)</measure>
    <time_frame>Three years of follow up within 2021 - 2025</time_frame>
    <description>The difference between infrequently and frequently screened unvaccinated women at the age of 28 is measured using RAND 36 to measure quality of life. It consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in infrequently vs. frequently screened unvaccinated women (EQ-VAS)</measure>
    <time_frame>Three years of follow up within 2021 - 2025</time_frame>
    <description>The difference between infrequently and frequently screened unvaccinated women at the age of 28 is measured using EQ-VAS a vertical visual analogue scale on which patients provide a global assessment of their health. The scale takes values between 100 (best imaginable health) and 0 (worst imaginable health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in infrequently vs. frequently screened unvaccinated women (CECA 10)</measure>
    <time_frame>Three years of follow up within 2021 - 2025</time_frame>
    <description>The difference between infrequently and frequently screened unvaccinated women at the age of 28 is measured using CECA 10, a Spanish acronym for the Specific Questionnaire for Condylomata Acuminata, summary scores of the emotional and sexual activity dimensions will be derived from CECA 10 scales. The CECA questionnaire includes 10 questions across 2 domains: emotional and sexual activity. CECA scores range from 0 (worst HRQL) to 100 (best HRQL)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <condition>Adenocarcinoma in Situ</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Frequent information of screening results for cytology and/or HPV DNA at the ages of 25 (cytology only) and 28 (cytology only) vs A2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>infrequent information of cytological screening/ HPV DNA results, only at the age 28 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The third arm with at 8000 participants devoid of herd effect protection and frequent screening at ages 25 and 28 is enrolled for comparative analyses between A1 vs. C and A2 vs. C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Frequent information of cytological/ HPV DNA screening results</intervention_name>
    <description>All participants will be referred to pertinent diagnosis and treatment according to local standard of care (Käypä hoito 2010) should the cytological screening results (HSIL, ASC-H, AGC-FN) or three consecutive LSIL findings at repeated control visits within 3 years indicate it. The most common screening results (ASCUS, LSIL) are, however, not convened to arm A2 participants before age 28.&#xD;
All cytology and HPV DNA results results are being revealed to all trial participants at age 28 at the study end.</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Born 1995-1997. 25 years of age residence in one of the eight community-randomized&#xD;
             trial A communities with documented herd effect from gender-neutral vaccination or C&#xD;
             communities devoid of the herd effect.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immune compromising disease status (e.g. transplant recipients). HPV vaccination&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matti Lehtinen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HUS</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Hämeenlinna</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Iisalmi</city>
        <zip>74100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Joensuu</city>
        <zip>80100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema, PSHP/ Tampereen yliopisto</name>
      <address>
        <city>Kemi</city>
        <zip>94100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema, PSHP/Tampereen yliopisto</name>
      <address>
        <city>Kotka</city>
        <zip>48100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Kouvola</city>
        <zip>45100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema, PSHP; Tampereen yliopisto</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema, PSHP/ Tampereen yliopisto</name>
      <address>
        <city>Lahti</city>
        <zip>15110</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Porvoo</city>
        <zip>06100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema, PSHP; Tampereen yliopisto</name>
      <address>
        <city>Rauma</city>
        <zip>26100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Sastamala</city>
        <zip>38200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuorisotutkimusasema; PSHP/ Tamereen yliopisto</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HPV-tutkimukset</name>
      <address>
        <city>Varkaus</city>
        <zip>78300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tampere University Hospital</investigator_affiliation>
    <investigator_full_name>Tiina Eriksson</investigator_full_name>
    <investigator_title>Research coordinator</investigator_title>
  </responsible_party>
  <keyword>Cervical Intraepithelial Neoplasia</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Carcinoma in Situ</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Neoplasms, Glandular and Epithelial</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Adenocarcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Adenocarcinoma in Situ</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

